MedTrace Logo

Liver-enriched Antimicrobial Peptide 2

NCT04043065 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2021-05-26

No results posted yet for this study

Summary

The investigators aim to investigate the physiological importance of LEAP-2 in healthy volunteers focusing on its potential insulinotropic effects.

Conditions

Interventions

BIOLOGICAL

Liver-enriched antimicrobial peptide 2

Infusion of LEAP-2 during a 180 min grated glucose infusion.

OTHER

Placebo

Saline

Sponsors & Collaborators

  • Gubra ApS

    collaborator UNKNOWN

  • University Hospital, Gentofte, Copenhagen

    lead OTHER

Principal Investigators

  • Filip K Knop, MD, PhD · University Hospital, Gentofte, Copenhagen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
25 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-01-28
Primary Completion
2019-05-20
Completion
2019-05-20

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04043065 on ClinicalTrials.gov